title: High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.
abstract: High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HDT/ASCT) can improve survival in patients with lymphoma. Limited experience is available on the safety and efficacy of HDT/ASCT in elderly patients. In this article, we review the published data on the role of HDT/ASCT in management of lymphoma in older patients. Based on available data, evaluation of comorbidities, functional status, and comprehensive geriatric assessment (CGA) will help identify those who can benefit most from this intervention. Prospective clinical trials focusing on HDT/ASCT in older patients with lymphoma are needed to establish optimal management protocols in this select population.
authors.affiliation: Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Oscar B
authors.initials: OB
authors.lastname: Lahoud
authors.forename: Craig S
authors.initials: CS
authors.lastname: Sauter
authors.forename: Paul A
authors.initials: PA
authors.lastname: Hamlin
authors.forename: Parastoo Bahrami
authors.initials: PB
authors.lastname: Dahi
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000628:therapy*; D018579:Patient Selection; D011446:Prospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous